Neutralizing Antibodies to Interferon-β and other Immunological Treatments for Multiple Sclerosis
- 1 May 2009
- journal article
- review article
- Published by Springer Nature in CNS Drugs
- Vol. 23 (5), 379-396
- https://doi.org/10.2165/00023210-200923050-00003
Abstract
Biopharmaceuticals can induce antibodies, which interact with and neutralize the therapeutic effect of such drugs and are therefore termed neutralizing antibodies (NAbs). In the treatment of multiple...Keywords
This publication has 102 references indexed in Scilit:
- Neutralizing anti-interferon beta antibodies are associated with reduced side effects and delayed impact on efficacy of Interferon-betaMultiple Sclerosis Journal, 2007
- The incidence and significance of anti-natalizumab antibodiesNeurology, 2007
- Immunogenicity and tolerability of an investigational formulation of interferon-β1a: 24- and 48-week interim analyses of a 2-year, single-arm, historically controlled, phase IIIb study in adults with multiple sclerosisClinical Therapeutics, 2007
- Magnetic resonance imaging as a surrogate outcome measure of disability in multiple sclerosis: Have we been overly harsh in our assessment?Annals of Neurology, 2006
- The role of MRI as a surrogate outcome measure in multiple sclerosisMultiple Sclerosis Journal, 2002
- Pure Red-Cell Aplasia and Antierythropoietin Antibodies in Patients Treated with Recombinant ErythropoietinNew England Journal of Medicine, 2002
- Daily urinary neopterin excretion as an immunological marker of disease activity in multiple sclerosisBrain, 1997
- Biological and Clinical Effects of Interferon-βserat Two DosesJournal of Interferon Research, 1990
- Rating neurologic impairment in multiple sclerosisNeurology, 1983
- Synthesis in E. coli of a polypeptide with human leukocyte interferon activityNature, 1980